©2024 Stanford Medicine
A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma
Recruiting
I'm InterestedTrial ID: NCT05972720
Purpose
This is a prospective, open-label, multi-center clinical study designed to evaluate the
safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of
CRG-022, a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the
treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Official Title
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-directed CAR T-cell Therapy
Stanford Investigator(s)
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Eligibility
Key Inclusion Criteria:
- Aged ≥18 years
- Relapsed or refractory large B-cell lymphoma.
- For enrollment in cohort 1, patients must have previously received a CD19-directed CAR
T-cell therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Adequate hematological, renal, and liver function
Key Exclusion Criteria:
- Clinically significant concurrent medical illness
- Active infection requiring systemic antibiotics
- Prior allogeneic stem cell transplant or allogeneic cell therapy
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention(s):
drug: Fludarabine (Conditional therapy)
drug: Cyclophosphamide Monohydrate (Conditional therapy)
drug: CRG-022 cells (Experimental drug)
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Kelly Chyan
650-625-8130